Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

Chinese Academy of Medical Sciences COVID-19 vaccine

From Wikipedia, the free encyclopedia
Vaccine against COVID-19

Pharmaceutical compound
Chinese Academy of Medical Sciences COVID-19 vaccine
Vaccine description
TargetSARS-CoV-2
Vaccine typeInactivated
Clinical data
Other namesCovidful (Chinese:科维福;pinyin:Kēwéifú)
Routes of
administration
Intramuscular
Legal status
Legal status
  • Emergency authorization: China[1]
Identifiers
CAS Number
DrugBank
Part ofa series on the
COVID-19 pandemic
Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom.
Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom.
virus iconCOVID-19 portal

Chinese Academy of Medical Sciences COVID-19 vaccine, orIMBCAMS COVID-19 vaccine, traded asCovidful (Chinese:科维福;pinyin:Kēwéifú), is aCOVID-19 vaccine developed byInstitute of Medical Biology, Chinese Academy of Medical Sciences [zh].

Clinical trials

[edit]

In May 2020, Covidful started phase I/II clinical trial with 942 participants in China.[3]

In January 2021, Covidful started phase III clinical trials with 34,020 from Brazil and Malaysia.[4]

Authorizations

[edit]
‹ Thetemplate below (Graph:Map) is being considered for deletion. Seetemplates for discussion to help reach a consensus. ›
This graph was using thelegacy Graph extension, which is no longer supported. It needs to be converted to thenew Chart extension.
  Full authorization
  Emergency authorization
  Allowed for travel
See also:List of COVID-19 vaccine authorizations § Chinese Academy of Medical Sciences

On 9 June 2021, The vaccine has been approved by the Chinese authorities.[1]

References

[edit]
  1. ^abLiu R, Woo R (9 June 2021)."China builds new plant for IMBCAMS COVID-19 vaccine -state media".Reuters. Retrieved15 June 2021.
  2. ^"Patent Landscape Report COVID-19-related vaccines and therapeutics"(PDF).
  3. ^Clinical trial numberNCT04412538 for "Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19" atClinicalTrials.gov
  4. ^Clinical trial numberNCT04659239 for "The Efficacy, Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19" atClinicalTrials.gov

External links

[edit]
logo
Pre-pandemic
2020
2021
2022
2023
Africa
Northern
Eastern
Southern
Central
Western
Asia
Central/North
East
Mainland China
South
India
By location
Southeast
Malaysia
Philippines
West
Europe
United Kingdom
By location
Eastern
Western Balkans
European Union
EFTA countries
Microstates
North
America
Atlantic
Canada
Caribbean
Countries
British Overseas Territories
Caribbean Netherlands
French West Indies
US insular areas
Central America
United States
responses
By location
Oceania
Australia
New Zealand
South
America
Others
Culture and
entertainment
Arts and
cultural heritage
Education
By country
Sports
By country
By sport
Society
and rights
Social impact
Labor
Human rights
Legal
Minority
Religion
Economic
By country
By industry
Supply and trade
Financial markets
Information
Misinformation
Politics
Political impact
Protests
International relations
Language
Others
Health issues
Medical topics
Testing and
epidemiology
Apps
Prevention
Vaccines
Topics
Authorized
DNA
Inactivated
mRNA
Subunit
Viral vector
Virus-like particles
In trials
Attenuated
DNA
Inactivated
RNA
Subunit
Viral vector
Virus-like particles
Deployment
by location
Africa
Asia
Europe
North America
Oceania
South America
Others
Treatment
Monoclonal antibodies
Small molecule antivirals
Specific
General
Institutions
Hospitals and
medical clinics
Mainland China
Others
Organizations
Health
institutes
Pandemic
institutes
Relief funds
People
Medical
professionals
Researchers
Officials
WHO
By location
Others
Data (templates)
Global
Africa
Americas
Asia
Europe
Oceania
Others
Development
Classes
Administration
Vaccines
Bacterial
Viral
Protozoan
Helminthiasis
Other
Inventors/
researchers
Controversy
Related
Pre-pandemic
2020
2021
2022
2023
Africa
Northern
Eastern
Southern
Central
Western
Asia
Central/North
East
Mainland China
South
India
By location
Southeast
Malaysia
Philippines
West
Europe
United Kingdom
By location
Eastern
Western Balkans
European Union
EFTA countries
Microstates
North
America
Atlantic
Canada
Caribbean
Countries
British Overseas Territories
Caribbean Netherlands
French West Indies
US insular areas
Central America
United States
responses
By location
Oceania
Australia
New Zealand
South
America
Others
Culture and
entertainment
Arts and
cultural heritage
Education
By country
Sports
By country
By sport
Society
and rights
Social impact
Labor
Human rights
Legal
Minority
Religion
Economic
By country
By industry
Supply and trade
Financial markets
Information
Misinformation
Politics
Political impact
Protests
International relations
Language
Others
Health issues
Medical topics
Testing and
epidemiology
Apps
Prevention
Vaccines
Topics
Authorized
DNA
Inactivated
mRNA
Subunit
Viral vector
Virus-like particles
In trials
Attenuated
DNA
Inactivated
RNA
Subunit
Viral vector
Virus-like particles
Deployment
by location
Africa
Asia
Europe
North America
Oceania
South America
Others
Treatment
Monoclonal antibodies
Small molecule antivirals
Specific
General
Institutions
Hospitals and
medical clinics
Mainland China
Others
Organizations
Health
institutes
Pandemic
institutes
Relief funds
People
Medical
professionals
Researchers
Officials
WHO
By location
Others
Data (templates)
Global
Africa
Americas
Asia
Europe
Oceania
Others
Portals:
Stub icon

This article about COVID-19 vaccines is astub. You can help Wikipedia byexpanding it.

Stub icon

This article about theCOVID-19 pandemic is astub. You can help Wikipedia byexpanding it.

Stub icon

This article aboutvaccines orvaccination is astub. You can help Wikipedia byexpanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Chinese_Academy_of_Medical_Sciences_COVID-19_vaccine&oldid=1247438266"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp